PLA2R and membranous nephropathy: A 3 year prospective Australian study

Area of Science:

• Nephrology
• Immunology
• Pathology

Background:

• Idiopathic membranous nephropathy (iMN) is a leading cause of nephrotic syndrome in adults.
• Phospholipase A2 receptor (PLA2R) is identified as the primary target antigen in iMN.
• Accurate diagnosis and monitoring of iMN are crucial for patient management.

Purpose of the Study:

• To determine the prevalence of anti-PLA2R antibodies in an Australian cohort of patients with iMN.
• To evaluate the diagnostic utility of serum anti-PLA2R testing and kidney biopsy PLA2R staining.
• To assess the correlation between anti-PLA2R levels and clinical outcomes.

Main Methods:

• Prospective study involving 21 iMN patients and 19 controls with secondary MN or other glomerular diseases.
• Serum anti-PLA2R antibodies were measured using enzyme-linked immunosorbent assay (ELISA) and indirect immunofluorescence.
• Kidney biopsies were examined for PLA2R deposition using polyclonal antibodies.

Main Results:

• Anti-PLA2R antibodies were detected in 81% of iMN patients by serum testing.
• PLA2R staining in kidney biopsies was observed in 14 iMN patients.
• 100% specificity for anti-PLA2R and glomerular PLA2R in iMN was demonstrated, with combined sensitivity reaching 95.2%.

Conclusions:

• This study confirms the high prevalence and diagnostic value of anti-PLA2R antibodies in Australian iMN patients.
• Combining serum anti-PLA2R testing with kidney biopsy PLA2R localization enhances diagnostic sensitivity.
• Monitoring anti-PLA2R titres can aid in assessing disease activity and treatment response in iMN.